Market Currents
Dyax (DYAX) -14% AH after declaring it will discontinue its Phase 2 trial for a drug meant to...
-
Thursday, June 14, 2012, 4:29 PM ETDyax (DYAX) -14% AH after declaring it will discontinue its Phase 2 trial for a drug meant to treat angiodema. Dyax says data from 72 patients taking part in the trials failed to produce a "statistically significant" difference in results for those taking its drug relative to those taking a placebo. Nonetheless, the company remains committed to broader angiodema drug development.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
